ZD-8731 HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 526927

CAS#: 135015-84-8 (HCl)

Description: ZD-8731, also known as ICI-D-8731 or D-8731, is an angiotensin type 1 receptor antagonist potentially for the treatment of hypertension and heart failure.

Price and Availability




ZD-8731 hydrochloride is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 526927
Name: ZD-8731 HCl
CAS#: 135015-84-8 (HCl)
Chemical Formula: C25H22ClN5O
Exact Mass: 443.1513
Molecular Weight: 443.935
Elemental Analysis: C, 67.64; H, 5.00; Cl, 7.99; N, 15.78; O, 3.60

Synonym: ZD-8731 hydrochloride; ZD-8731; ZD 8731; ZD8731; ICI-D-8731; ICI-D 8731; ICI-D8731; D-8731.

IUPAC/Chemical Name: 2-Ethyl-4-((2'-(1H-1,2,3,4-tetrazol-5-yl)biphenyl-4-yl)methoxy)quinoline hydrochloride


InChi Code: InChI=1S/C25H21N5O.ClH/c1-2-19-15-24(22-9-5-6-10-23(22)26-19)31-16-17-11-13-18(14-12-17)20-7-3-4-8-21(20)25-27-29-30-28-25;/h3-15H,2,16H2,1H3,(H,27,28,29,30);1H


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:

Additional Information

Related CAS#
143494-72-8 (ZD-8731 free base)
135015-84-8 (ZD-8731 hydrochloride)


1: Geiger H, Fierlbeck W, Mai M, Ruchti H, Schönfeld V, Dämmrich J, Hugo C, Neumayer HH. Effects of early and late antihypertensive treatment on extracellular matrix proteins and mononuclear cells in uninephrectomized SHR. Kidney Int. 1997 Mar;51(3):750-61. PubMed PMID: 9067907.

2: Hoenack C, Roesen P. Inhibition of angiotensin type 1 receptor prevents decline of glucose transporter (GLUT4) in diabetic rat heart. Diabetes. 1996 Jan;45 Suppl 1:S82-7. PubMed PMID: 8529806.

3: Brilla CG, Zhou G, Rupp H, Maisch B, Weber KT. Role of angiotensin II and prostaglandin E2 in regulating cardiac fibroblast collagen turnover. Am J Cardiol. 1995 Nov 2;76(13):8D-13D. Review. PubMed PMID: 7495221.

4: Shaw LM, George PR, Oldham AA, Heagerty AM. A comparison of the effect of angiotensin converting enzyme inhibition and angiotensin II receptor antagonism on the structural changes associated with hypertension in rat small arteries. J Hypertens. 1995 Oct;13(10):1135-43. PubMed PMID: 8586805.

5: Toubro S, Christensen NJ, Astrup A. Reproducibility of 24-h energy expenditure, substrate utilization and spontaneous physical activity in obesity measured in a respiration chamber. Int J Obes Relat Metab Disord. 1995 Aug;19(8):544-9. PubMed PMID: 7489024.

6: Bauer JH, Reams GP. The angiotensin II type 1 receptor antagonists. A new class of antihypertensive drugs. Arch Intern Med. 1995 Jul 10;155(13):1361-8. Review. PubMed PMID: 7794084.

7: Regitz-Zagrosek V, Auch-Schwelk W, Hess B, Klein U, Duske E, Steffen C, Hildebrandt AG, Fleck E. Tissue- and subtype-specific modulation of angiotensin II receptors by chronic treatment with cyclosporin A, angiotensin-converting enzyme inhibitors and AT1 antagonists. J Cardiovasc Pharmacol. 1995 Jul;26(1):66-72. PubMed PMID: 7564368.

8: Doughty SE, Ferrier RK, Hillan KJ, Jackson DG. The effects of ZENECA ZD8731, an angiotensin II antagonist, on renin expression by juxtaglomerular cells in the rat: comparison of protein and mRNA expression as detected by immunohistochemistry and in situ hybridization. Toxicol Pathol. 1995 May-Jun;23(3):256-61. PubMed PMID: 7659950.

9: Auch-Schwelk W, Duske E, Hink U, Betz M, Unkelbach M, Fleck E. Vasomotor responses in cyclosporin A-treated rats after chronic angiotensin blockade. Hypertension. 1994 Jun;23(6 Pt 2):832-7. PubMed PMID: 8206613.

10: Maxfield EK, Cameron NE, Cotter MA, Dines KC. Angiotensin II receptor blockade improves nerve function, modulates nerve blood flow and stimulates endoneurial angiogenesis in streptozotocin-diabetic rats and nerve function. Diabetologia. 1993 Dec;36(12):1230-7. PubMed PMID: 8307249.

11: Pörsti I, Hecker M, Bassenge E, Busse R. Dual action of angiotensin II on coronary resistance in the isolated perfused rabbit heart. Naunyn Schmiedebergs Arch Pharmacol. 1993 Dec;348(6):650-8. PubMed PMID: 7510856.

12: Masek BB, Merchant A, Matthew JB. Molecular shape comparison of angiotensin II receptor antagonists. J Med Chem. 1993 Apr 30;36(9):1230-8. PubMed PMID: 8487259.

13: Bradbury RH, Allott CP, Dennis M, Fisher E, Major JS, Masek BB, Oldham AA, Pearce RJ, Rankine N, Revill JM, et al. New nonpeptide angiotensin II receptor antagonists. 2. Synthesis, biological properties, and structure-activity relationships of 2-alkyl-4-(biphenylylmethoxy)quinoline derivatives. J Med Chem. 1992 Oct 30;35(22):4027-38. PubMed PMID: 1433210.